New Funding to Propel Newronika's Adaptive DBS Platform
Newronika, a leader in advanced deep brain stimulation technology, has successfully closed a significant €13.6 million Series B funding round aimed at accelerating the development of its innovative adaptive DBS platform. This exciting news comes as the company continues its mission to transform neurological treatment by integrating cutting-edge technology into its procedures.
Investors Join Forces for a Common Goal
This funding round was primarily led by the Fondazione ENEA Tech e Biomedical, a fresh investor in Newronika, joined by esteemed existing investors such as Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F. The participation of both new and existing investors shows a strong vote of confidence in Newronika's vision and capabilities.
Expanding Clinical Validation and Product Pipeline
The financial backing will enable Newronika to enhance the clinical validation and commercialization phases of its adaptive DBS system, a unique platform designed to deliver tailored therapies that alleviate Parkinson's symptoms while minimizing side effects. Furthermore, these funds will help the company recruit top talent and forge strategic partnerships to solidify its leadership in the evolving medical device landscape.
Commitment to a New Era in Neuromodulation
Newronika has seen significant momentum in recent months, including receiving a grant from The Michael J. Fox Foundation and having secured Investigational Device Exemption approval from the FDA. These achievements, alongside the new funding, underline the company’s mission of spearheading a shift in neuromodulation approaches.
Visionaries Behind Newronika's Success
Dr. Lorenzo Rossi, Co-Founder and CEO of Newronika, enthusiastically remarked, "We are thrilled with the strong support from both new and existing investors. This Series B round validates our commitment to transforming how deep brain stimulation is delivered by seamlessly integrating real-time neural data with machine learning into our DBS systems. Our goal is to create personalized therapies that exceed the current market offerings."
Insights from ENEA Tech e Biomedical
Maria Cristina Porta, General Manager of ENEA Tech e Biomedical, expressed her excitement about the collaboration, stating, "With Newronika and its adaptive DBS platform, we see extraordinary potential to revolutionize treatment for movement disorders on a global scale. Their approach of real-time personalized neuromodulation aligns perfectly with our vision to support disruptive medical technologies.”
Future Prospects and Patient Impact
Davide Turco, CEO of Indaco, echoed similar sentiments noting, "Indaco is proud to continue supporting Newronika in its upcoming clinical and commercial phases. We firmly believe that this adaptive DBS system will significantly improve the quality of life for many Parkinson's patients." The enthusiasm and investment from top-tier partners signal a promising future for Newronika's innovative technologies.
Strategic Vision of Newronika
Claudio Giuliano, Chairman of Newronika, commented, "This successful Series B financing round genuinely solidifies Newronika's strategic vision, pushing the limits of DBS technology to enhance patient outcomes." Newronika's commitment to progress emphasizes the importance of harnessing technology to improve health and transform lives.
About Newronika
Headquartered in Milan, Italy, Newronika is at the forefront of deep brain stimulation innovation with its adaptive platform that optimizes therapy through real-time patient data. The company’s focus on advancing neuromodulation technology is evident through its ongoing research partnerships, CE Mark for its devices, and FDA Investigational Device Exemption.
Frequently Asked Questions
What is Newronika's main focus?
Newronika focuses on advancing deep brain stimulation (DBS) technology to optimize therapy for neurological disorders, particularly Parkinson’s disease.
How much funding did Newronika secure?
Newronika successfully raised €13.6 million in their recent Series B financing round.
Who led the recent funding round?
The funding round was led by Fondazione ENEA Tech e Biomedical, along with participation from existing investors.
What are adaptive DBS systems?
Adaptive DBS systems are innovative neuromodulation platforms that use real-time neural data to deliver personalized therapy for Parkinson's disease patients.
Where is Newronika headquartered?
Newronika is headquartered in Milan, Italy, where it focuses on advancing its cutting-edge technology and treatment approaches.
